Avastin ®

Generic name: Bevacizumab

Chemocare.com uses generic names in all descriptions of drugs. Avastin is the trade name for Bevacizumab. In some cases, health care professionals may use the trade name Avastin when referring to the generic drug name Bevacizumab.

Drug type: Avastin is classified as a "monoclonal antibody" and "anti-angiogenesis" drug. (For more detail, see "How this drug works" section below.)

What Avastin is used for:

Note: If avastin has been approved for one use, physicians may elect to use avastin for other problems if they believe it may be helpful.

How Avastin is given:

Side effects of Avastin:
Important things to remember about the side effects of avastin:

The following side effects are common (occurring in greater than 30%) for patients taking avastin:

These side effects are less common side effects (occurring in about 10-29%) of patients receiving avastin:

These are rare but serious complications of avastin therapy.

Delayed effects:

Not all side effects are listed above. Some that are rare (occurring in less than 10% of patients) are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms.

When to contact your doctor or health care provider:

Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:

The following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any of the following:

Always inform your health care provider if you experience any unusual symptoms.

Precautions:

Self-care tips:

Monitoring and testing:

You will be checked regularly by your health care professional while you are taking avastin, to monitor side effects and check your response to therapy. Periodic blood work to monitor your complete blood count (CBC) as well as the function of other organs (such as your kidneys and liver) will also be ordered by your doctor.

How Avastin works:

Monoclonal antibodies are a relatively new type of "targeted" cancer therapy. Antibodies are part of the immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a germ) entering the body. The antibodies attach to the antigen in order to mark it for destruction by the body's immune system. In the laboratory, scientists analyze specific antigens on the surface of cancer cells (target) to determine a protein to match the antigen. Then, using animal and human proteins, scientists work to create a special antibody that will attach to the target antigen. Antibodies will attach to matching antigens like a key fits a lock. This technology allows treatment to target specific cells, causing less toxicity to healthy cells. Monoclonal antibody therapy can be done only for cancers in which antigens (and the respective antibodies) have been identified.

Avastin works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis.

Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educational, but is not a substitute for medical advice.